Report primary endpoint data for the EDELWEISS 3 study
Delivered after the deadline (6 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- 6 Jan 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Primary Endpoint Readout Expected 4Q 2021”
What we found
Evidence strength A What the grades mean
The company announced the topline results for the EDELWEISS 3 trial on January 6, 2022, which is after the 4Q 2021 deadline.
-
A ObsEva S.A. 6-K filed 2022-01-06
“ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain” ✓ confirmed on the page
-
A ObsEva S.A. 6-K filed 2022-03-10
“On January 6, 2022, ObsEva announced positive topline results from the Phase 3 EDELWEISS 3 trial in women with moderate-to-severe endometriosis-associated pain.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- EDELWEISS 3 primary endpoint data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you ObsEva S.A.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C685316-021803 · Corrections policy